Core Insights - EDAP TMS SA reported its strongest second quarter performance in company history, with a net total of 12 Focal One Robotic HIFU Systems placed, driven by increased customer demand from both U.S. and international markets [2][6] - The company executed a letter of intent with the European Investment Bank for a credit facility of 36 million Euros to support the expansion of its Focal One platform and focused ultrasound technologies [2][8] - The company anticipates continued growth in demand for Focal One treatments as more prostate cancer patients recognize its advantages, supported by recent clinical studies [2][6] Financial Performance - Total revenue in the HIFU business for Q2 2025 was EUR 8.5 million (USD 9.7 million), a 76.8% increase from EUR 4.8 million (USD 5.2 million) in Q2 2024 [6][9] - The company recorded a 23.9% year-over-year growth in worldwide disposable revenue, with Focal One procedures growing 4.8% in the U.S. [6][9] - Total worldwide revenue for Q2 2025 was EUR 16.0 million (USD 18.4 million), a slight increase of 1.6% compared to EUR 15.8 million (USD 17.0 million) in Q2 2024 [9] Business Segments - The non-core business (ESWL and Distribution) revenue for Q2 2025 was EUR 7.6 million (USD 8.7 million), down from EUR 11.0 million (USD 11.8 million) in Q2 2024, reflecting a strategic focus on the high-growth HIFU opportunity [7][9] - For the first half of 2025, total revenue in the HIFU business was EUR 14.7 million (USD 16.1 million), a 38.5% increase from EUR 10.6 million (USD 11.4 million) in the same period of 2024 [13] - The non-core business revenue for the first half of 2025 was EUR 15.0 million (USD 16.5 million), a 25.7% decrease compared to EUR 20.1 million (USD 21.7 million) in the first half of 2024 [14] Profitability Metrics - Gross profit for Q2 2025 was EUR 6.8 million (USD 7.8 million), with a gross profit margin of 42.5%, up from 37.5% in Q2 2024 [10] - Operating loss for Q2 2025 was EUR 5.8 million (USD 6.6 million), an improvement from an operating loss of EUR 6.1 million (USD 6.6 million) in Q2 2024 [11] - Net loss for Q2 2025 was EUR 5.6 million (USD 6.4 million), or EUR (0.15) per share, compared to a net loss of EUR 6.1 million (USD 6.6 million), or EUR (0.16) per share in Q2 2024 [12] Future Outlook - The company updated its 2025 financial guidance, expecting core HIFU business revenue growth to be between 26% and 34% year-over-year, up from the previous range of 16% to 25% [5][7] - The combined non-core ESWL and Distribution business revenue is expected to decline between 25% and 30% year-over-year [5][7] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025 [4]

The Cooper Companies (COO) Q3 2025 Earnings Call August 27, 2025 05:00 PM ET Company ParticipantsKim Duncan - VP of IR & Risk ManagementAlbert White - President, CEO & DirectorBrian Andrews - EVP, CFO & TreasurerJonathan Block - Managing DirectorIssie Kirby - VP - Equity Research, Medical Technology & Life SciencesJoanne Wuensch. - Managing DirectorBradley Bowers - VP - Equity ResearchPatrick Wood - Managing DirectorConference Call ParticipantsLawrence Biegelsen - Senior Medical Device Equity Research Analy ...

The Cooper Companies (COO) Q3 2025 Earnings Call August 27, 2025 05:00 PM ET Speaker0Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 twenty twenty five Cooper Companies Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session.I would now like to turn the conference over to Kim ...

1. Guidance updated 8/27/25. CooperCompanies Fiscal 2025 & Q4'25 financial guidance | | | | FY25 Guidance | Q4 2025 Guidance | | --- | --- | --- | --- | --- | | | Total | $4,076 - | $4,096 | $1,049 - $1,069 | | | | (4% - | 4.5% organic growth) | (2% - 4% organic growth) | | s e al S | CooperVision | $2,734 - | $2,747 | $700 - $713 | | | | (4% - | 5% organic growth) | (2% - 4% organic growth) | | | CooperSurgical | $1,343 - | $1,349 | $350 - $356 | | | | (3% - | 3.5% organic growth) | (2% - 4% organic growth ...

SAN RAMON, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2025. Revenue increased 6% year-over-year to $1,060.3 million. CooperVision (CVI) revenue up 6% to $718.4 million, and CooperSurgical (CSI) revenue up 4% to $341.9 million.GAAP diluted earnings per share (EPS) of $0.49, down $0.03 or 6% from last year's third quarter.Non-GAAP diluted EPS of $1.10, up $0.14 o ...

Key Takeaways Abbott posted Q2 gross profit of $6.29B, up 8.9% year over year, with margin expansion to 56.4%. Strong growth in ABT's Medical Devices and Nutrition drove a favorable product mix and higher-margin sales.FX tailwinds, and reduced COVID testing drag reinforced ABT's margin gains despite macro issues. In the second quarter, Abbott Laboratories (ABT) posted gross profit of $6.29 billion, up 8.9% year over year despite a 5.4% increase in the cost of products sold (excluding amortization expense). ...

Key Takeaways IDEXX posted 11% organic growth in international CAG diagnostic recurring revenues in Q2 2025.IDXX's cloud-native PIMS platforms ezyVet and Neo saw double-digit placement growth in the second quarter.IDEXX ended Q2 2025 with $164.6M in cash versus $654M in short-term debt and $450M long-term debt.IDEXX Laboratories, Inc.’s (IDXX) second-quarter growth was backed by the robust performance of its CAG (Companion Animal Group) Diagnostics business. The consistent growth in international CAG diagno ...

MIAMI, Aug. 27, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10th at 10:00am Eastern Time (ET). A live audio webcast and replay of the presentation may be accessed on the “Investor Calendar” section of the company’s website at: https://inspiremd.com/investors/investor-calendar/ About Ins ...

ALAMEDA, Calif., Aug. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced the promotion of Shruthi Narayan to President of the company, effective September 1, 2025. She will continue to report to Adam Elsesser, who served in the role of President prior to this promotion and will continue in his roles as chairman of the board and chief executive officer of Penumbra. Except for historical information, certain statements in this press release are forwa ...

ALACHUA, Fla. and TAMPA, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in four upcoming investor conferences: Cantor Global Healthcare Conference (NYC)Participation: Fireside chat and 1x1 investor meetings Date/Time: Fireside Chat Wednesday, September 3, 2025, 3:20 PM ETWebcast Link: Cantor/Axogen Firesi ...